- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics of crizotinib in NSCLC patients
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 11, Issue 5, Pages 835-842
Publisher
Informa Healthcare
Online
2015-03-03
DOI
10.1517/17425255.2015.1021685
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EML4-ALK Fusion Lung Cancer: A Rare Acquired Event
- (2015) Sven Perner et al. NEOPLASIA
- The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials
- (2014) Haili Qian et al. BMC CANCER
- U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
- (2014) S. M. Malik et al. CLINICAL CANCER RESEARCH
- ALK Inhibitors: What Is the Best Way to Treat Patients With ALK+ Non–Small-Cell Lung Cancer?
- (2014) Gouji Toyokawa et al. Clinical Lung Cancer
- Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
- (2014) Christian Rolfo et al. Expert Review of Anticancer Therapy
- Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects
- (2014) Huiping Xu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
- (2014) D. Kazandjian et al. ONCOLOGIST
- Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer
- (2014) Lin Yang et al. TUMOR BIOLOGY
- Novel agents in development for advanced non-small cell lung cancer
- (2014) Thomas E. Stinchcombe Therapeutic Advances in Medical Oncology
- A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer
- (2014) Khashayar Esfahani et al. Frontiers in Oncology
- Crizotinib for the treatment of non-small-cell lung cancer
- (2013) A. Timm et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models
- (2013) N. Miyajima et al. CANCER RESEARCH
- Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer
- (2013) B Solomon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer
- (2013) James E. Frampton DRUGS
- Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
- (2013) Seng Chuan Tang et al. INTERNATIONAL JOURNAL OF CANCER
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement
- (2013) Denis Maillet et al. Journal of Thoracic Oncology
- High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib
- (2013) Young Hak Kim et al. Journal of Thoracic Oncology
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
- (2013) Yael P Mossé et al. LANCET ONCOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Translational Pharmacokinetic-Pharmacodynamic Modeling from Nonclinical to Clinical Development: A Case Study of Anticancer Drug, Crizotinib
- (2012) Shinji Yamazaki AAPS Journal
- Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
- (2012) Wen-jing Zhou et al. BRITISH JOURNAL OF PHARMACOLOGY
- Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer
- (2012) Andrew J. Weickhardt et al. CANCER
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
- (2010) Xuchao Zhang et al. Molecular Cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More